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To evaluate the use of diffusion-weighted magnetic resonance imaging 3 
(DW-MRI) and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for 4 
predicting disease progression (DP) among patients with non-small cell lung carcinoma 5 
(NSCLC) treated with stereotactic body radiotherapy (SBRT).  6 
 7 
Materials/Methods 8 
Fifteen patients with histologically confirmed stage I NSCLC who underwent 9 
pre-treatment DW-MRI and PET and were treated with SBRT were enrolled. The mean 10 
apparent diffusion coefficient (ADC) value and maximum standardised uptake value 11 
(SUVmax) were measured at the target lesion and evaluated for correlations with DP. 12 
 13 
Results 14 
The median pre-treatment ADC value was 1.04 × 10-3 (range 0.83–1.29 × 10-3) 15 
mm2/s, and the median pre-treatment SUVmax was 9.9 (range 1.6–30). There was no 16 
correlation between the ADC value and SUVmax. The group with the lower ADC value (≤ 17 
1.05 × 10-3 mm2/s) and that with a higher SUVmax (≥ 7.9) tended to have poor DP, but 18 
neither trend was statistically significant (p = 0.09 and 0.32, respectively). The 19 
combination of the ADC value and SUVmax was a statistically significant predictor of DP 20 
(p = 0.036). 21 
 22 
Conclusion 23 
A low ADC value on pre-treatment DW-MRI and a high SUVmax may be 24 
associated with poor DP in NSCLC patients treated with SBRT. Using both values in 25 
combination was a better predictor.  26 
Introduction 27 
Surgery is widely accepted as a standard therapy for stage I non-small cell lung 28 
cancer (NSCLC); however, some patients with stage I NSCLC are not suited for resection 29 
mainly because of their poor respiratory function. 30 
Stereotactic body radiotherapy (SBRT) has recently been accepted as an 31 
alternative therapy for patients with stage I NSCLC who cannot undergo surgery or 32 
decline surgery [1-3]. In a previous study, medically inoperable patients were treated with 33 
peripheral T1-T2N0M0 NSCLC using SBRT [4]; the authors reported 3-year local control 34 
rates of 97.6% in a group of 55 patients with a median follow-up of almost 3 years, but 35 
distant metastasis was 22.1%. We previously reported a 3-year local control rate of 86.8% 36 
and a progression-free rate of 59.2% [5]. 37 
Histological findings are important factors for the determination of a treatment 38 
strategy and to predict clinical outcomes [6]. In lung SBRT, pathological diagnosis is 39 
confirmed in most patients before treatment is administered, however some patients 40 
undergo the treatment without histological confirmation due to the risk of adverse events 41 
caused by biopsy. Simple and less-invasive alternative methods are needed to stratify 42 
patients according to risk of disease progression (DP). 43 
Advances in imaging technologies such as diffusion-weighted magnetic resonance 44 
imaging (DW-MRI) and 18F-fluorodeoxyglucose (FDG) positron emission tomography 45 
(PET) have made it possible to evaluate not only morphological aspects, but also 46 
functional aspects including diffusion motion of water molecules and glucose metabolism 47 
in tumours. These recently developed imaging techniques are applied to improve the 48 
sensitivity of tumour detection and prediction accuracy of the clinical outcomes. Several 49 
studies have analysed the utility of FDG-PET for the prognosis and prediction of 50 
therapeutic effect after treatment of NSCLC [7-9]. The apparent diffusion coefficient 51 
(ADC) of a tumour based on DW-MRI has been reported to be a useful indicator for early 52 
prediction of tumour response and prognosis in other cancers treated with 53 
chemoradiotherapy [10, 11]. To date, no study has evaluated the use of DW-MRI as a 54 
predictor for NSCLC treated with SBRT. Several studies have found that PET might be a 55 
useful predictor for patients with early-stage NSCLC treated with SBRT, but the results 56 
are controversial [12-15]. 57 
In this study, we evaluated whether pre-treatment DW-MRI and PET could be 58 
used to predict the clinical outcome of stage I NSCLC outcomes after SBRT and 59 




The eligibility criteria for lung SBRT in our hospital were as follows: (1) 64 
T1a-T2aN0M0 lung tumour, (2) inoperable or refusal to undergo surgery, (3) arms could 65 
be held over the head for 30 min or more, and (4) performance status of 0–2. 66 
Fifteen patients with histologically confirmed NSCLC who underwent 67 
pre-treatment DW-MRI and FDG-PET and were treated with SBRT in our hospital 68 
between January and December of 2010 were included this study. This study was 69 
approved by our Institutional Review Board. The median age was 80 years (range, 70–86 70 
years). Eleven patients were male and four were female. Patients were staged according to 71 
the Union for International Cancer Control’s TNM classification, 7th edition with CT and 72 
FDG-PET. Contrast medium was administered in the CT scan, if possible. The mean 73 
diameter of the tumours was 28 mm (range, 14–42 mm). T stages were distributed as 74 
follows: T1a in four, T1b in six, and T2a in five patients. Histological examinations 75 
included transbronchial biopsy (10 patients) or percutaneous CT-guided biopsy (5 76 
patients) and were conducted before the pre-treatment DW-MRI and FDG-PET. The 77 
median interval between the biopsy and these imaging was 43 days (range, 17–67 days). 78 
The detailed characteristics of all patients are shown in Table 1. 79 
 80 
SBRT procedure 81 
The details of the SBRT procedure were described previously [16]. The patient’s 82 
body was immobilised with an individualised vacuum pillow  (BodyFIX; Elekta AB, 83 
Stockholm, Sweden). The SBRT protocol was created with a commercial treatment 84 
planning system, iPlan (BrainLab, Feldkirchen Germany). Four-dimensional computed 85 
tomography (4DCT) data were acquired in axial cine mode using a 16-slice CT scanner 86 
(LightSpeed RT16, GE Healthcare, Waukesha, WI, USA) and real-time positioning 87 
management system (Varian Medical Systems, Palo Alto, CA, USA). An internal target 88 
volume (ITV) was determined by assessing tumour trajectory using 4DCT and tumour 89 
motion by X-ray fluoroscopy. Both techniques were employed because 4DCT is only 90 
capable of evaluating one respiratory cycle, and X-ray fluoroscopy can be used to evaluate 91 
the changes of tumour motion amplitude and duration of the respiratory cycle in several 92 
respiratory cycles. Planning target volume (PTV) was defined as ITV + margin (5mm). 93 
Irradiation was performed with 6 MV X-ray beams from a linear accelerator 94 
(Novalis BrainLab) in multiple coplanar and noncoplanar static ports (6 to 8 ports). The 95 
dose was prescribed to the isocentre and dose distribution in PTV was homogeneous. The 96 
70%-80% isodose lines encompassed the PTV edge. Dose distribution was calculated 97 
with the X-ray Voxel Monte Carlo method. 98 
Prescribed doses and fractions were 48 Gy/4 fr (biologically effective dose [BED] 99 
of 105.6 Gy10) for T1a-T1b, 56 Gy/4 fr (BED 134.0 Gy10) for T2a, and 60 Gy/8 fr (BED 100 
105.0 Gy10) for centrally located tumours within 2 cm of the trachea or proximal bronchial 101 
tree, great vessels, and other mediastinal structures, regardless of their size. Overall 102 
treatment time was 4 to 11 days. 103 
 104 
MRI protocol 105 
All MRI examinations were performed using a 1.5T MR unit (Avanto, Siemens, 106 
Erlangen, Germany) with a phased-array coil. All patients were imaged in the supine 107 
position. Initially, transverse HASTE images were obtained for anatomical identification. 108 
Subsequently, both T2-weighted (TR/TE = 2100/85 ms) and DW-MR images with 109 
prospective acquisition correlation (PACE) utilising sensitivity encoding (SENSE; with a 110 
SENSE factor of 2) and echo planar imaging (EPI; with an EPI factor of 96) were 111 
obtained. The parameters used for DW-MRI were a TR/TE of 2746.3–12030.4/72–79 ms, 112 
FOV of 320 mm, slice thickness of 4.0 mm, matrix of 96 × 128 mm, band width of 1860 113 
Hz/pixel and five excitations. All DW-MR images were acquired with MPG pulses in 114 
three directions (the x, y, and z axes) with three different b-factors (0, 500, and 1000 115 
s/mm2). All MR images covered the entire chest. ADC maps were automatically 116 
calculated from a series of DW images according to a linear regression model based on 117 
the logarithm of signal intensities as follows: 118 
ADC = (log SI1/SI0)/b 119 
where SI1 is the signal intensity with a diffusion gradient, SI0 is the signal intensity 120 
without a diffusion gradient, and b is the gradient factor of sequences. 121 
The ADC values of each tumour were measured by a single observer (SU) with 10 122 
years of experience in clinical chest MRI. The mean signal intensity of the tumour was 123 
measured on an ADC map within three different circular regions of interest (ROIs) that 124 
were as large as possible. The average of these was calculated as the ADC value of the 125 
tumour. All ROIs were established in the centre of the tumour to avoid artefacts from the 126 
tumour/air interface or from blood flow in the surrounding large vessels. T2-weighted MR 127 
images were also used as a reference, to avoid inclusion of necrotic areas in the ROIs. The 128 
respiratory gating method was used for the MRI scan. 129 
 130 
FDG-PET protocol 131 
Patients fasted for at least 4 h before the examination, and their plasma glucose 132 
level was checked immediately before the administration of 18F-FDG (~3.7 MBq/kg). No 133 
patients had a plasma glucose level greater than 200 mg/dL. Approximately 1 h later, 134 
PET/CT was performed, using a combined PET/CT scanner (Discovery ST Elite, GE 135 
Healthcare Waukesha, WI, USA). Low-dose CT images were acquired during shallow 136 
breathing from the upper thigh to the skull base with a 16-detector row scanner (20–100 137 
mA, using the auto-mA setting with a noise index of 30, 120 kV, 0.6 s tube rotation, slice 138 
thickness 3.75 mm, matrix 512×512, and a pitch of 1.75). Immediately after CT, a 139 
whole-body PET emission scan was performed in 3D-acquisition mode with an 140 
acquisition time of 2–3 min per bed position. The PET images were attenuation-corrected 141 
using the CT data and were reconstructed with a 3D ordered-subsets expectation 142 
maximisation algorithm. The respiratory gating method was not used for the PET scan. 143 
The maximum standardised uptake values (SUVmax) were measured at the target lesion by 144 
a single observer (YN) with more than 10 years of experience in nuclear medicine. 145 
 146 
Follow-up 147 
Follow-up visits were conducted at 1, 2, 3, 6, 9, and 12 months in the first year 148 
after SBRT and every 3–6 months thereafter. The plain CT scan was performed every 3 149 
months in the first year after treatment and every 3–6 months thereafter. When DP was 150 
highly suspected by the CT scan, FDG-PET was also performed. 151 
Local progression (LP) was diagnosed based on the recommendations for 152 
follow-up imaging established by Huang et al. [17]. Regional lymph node metastases 153 
were diagnosed based on CT. FDG-PET results were also considered in diagnosis but 154 
histological confirmation was not mandatory. DP was defined as LP, regional lymph node 155 
metastases, or distant metastases. 156 
 157 
Statistical analysis  158 
The correlation of ADC value and SUVmax with DP after SBRT was evaluated. LP 159 
and overall survival (OS) were evaluated in the same manner. To consider the impact that 160 
the tumour diameter gives the ADC value and SUVmax, the correlations of ADC value and 161 
SUVmax with tumour size were also evaluated. The cumulative incidence of DP and LP 162 
was evaluated considering competing risk of non-lung cancer death. The Kaplan–Meier 163 
method was used to estimate OS and the Grey-box test and log-rank test were used to 164 
detect differences between strata. A p-value < 0.05 was considered statistically significant. 165 
Receiver operating characteristic (ROC) analyses were performed to determine 166 
appropriate thresholds of ADC value and SUVmax. All statistical analyses were performed 167 




The median follow-up period was 28.0 (range, 6.7–37.2) months. DP was 172 
observed in nine patients. The first site of progression was local tumour in three patients, 173 
regional lymph node in two patients, and distant metastasis in four patients. Seven of the 174 
nine DP were diagnosed with CT and FDG-PET. The remaining two patients who 175 
developed lung metastases were diagnosed with plain CT. 176 
The OS at 24 months was 52% (seven patients died, 95% confidence interval [CI], 177 
26–74%). The cumulative incidence rates of LP and DP were 16% (two patients) and 57%, 178 
(nine patients) respectively, at 24 months. 179 
ADC value and SUVmax 180 
The pre-treatment ADC values ranged from 0.83 to 1.29 × 10-3 mm2/s (median 181 
1.04 × 10-3 mm2/s), and SUVmax ranged from 1.5 to 30.0 (median 9.9). There was no 182 
statistically significant correlation between ADC value and SUVmax (Fig. 1). Fig. 2 shows 183 
the scatter plot of tumour diameter and ADC value and SUVmax. ADC value and SUVmax 184 
showed weak positive correlations with tumour diameter with correlation coefficients of 185 
0.48 and 0.50, but without statistical significance (p = 0.64 and 0.63, respectively). 186 
According to the ROC analysis the appropriate threshold values for DP were 1.05 × 10-3 187 
mm2/s for ADC value and 7.9 for SUVmax. 188 
When dividing the patients into two groups according to the threshold ADC value 189 
of 1.05 × 10-3 mm2/s, the group with the lower ADC value had worse DP compared to 190 
patients with the higher ADC value (80% and 20%, respectively, at 24 months). There 191 
was a similar tendency in the group with the higher SUVmax (≥ 7.9) to have a poor DP 192 
(60% and 40%, respectively, at 24 months). However, neither DP trend was statistically 193 
significant. (p = 0.09, and 0.32, respectively). 194 
As an exploratory analysis, a combination of ADC value and SUVmax with the 195 
same threshold values was investigated. When patients were divided into two groups 196 
(high-risk group: patients with ADC value ≤ 1.05 × 10-3 mm2/s and SUVmax ≥ 7.9; and 197 
low-risk group: all other patients), the numbers of patients were well balanced between 198 
the groups (8 and 7 patients for the high- and low-risk groups, respectively). The high-risk 199 
group had significantly worse DP (p = 0.036). The cumulative incidence rates of DP were 200 
75.0% (six patients) in the high-risk group and 28.6% (two patients) in the low-risk 201 
groups, respectively, at 24 months (Fig. 3). The two groups had a similar number of 202 
patients, and similar characteristics (Table 2). 203 
The OS at 24 months was 50% (four patients died) in the high-risk group and 57% 204 
(three patients died) in the low-risk group. However, from the viewpoint of cancer specific 205 
death, the survival rates were 60% (three patients died) in the high-risk group and 83% 206 
(one patient died) in the low-risk group. The cumulative incidence rates of LP at 24 207 
months were 14% (one patient) in both groups. The tumour diameter, pre-treatment ADC 208 
value and SUVmax of the patient in the high-risk group were 28 mm, 1.04 × 10-3 mm2/s 209 
and 7.9. Those of the patient in the low-risk group were 42 mm, 1.19 × 10-3 mm2/s and 210 
13.6, respectively. 211 
 212 
Discussion 213 
To the best of our knowledge, this is the first study to evaluate the use of 214 
DW-MRI for predicting the clinical outcomes in NSCLC patients treated with SBRT. It is 215 
also the first direct comparison of FDG-PET and DW-MRI in terms of prognosis 216 
prediction for NSCLC patients who have undergone SBRT. 217 
We found that patients presenting with stage I NSCLC and either a lower ADC 218 
value, or with a higher SUVmax tended to have a poor DP after SBRT although the 219 
difference was not statistically significant. The use of ADC value and SUVmax in 220 
combination was a better predictor for DP than either biological marker alone. 221 
Several previous studies on PET in NSCLC patients treated with SBRT have been 222 
published. Various controversial results have been reported regarding the use of 223 
FDG-PET for prognosis. In a recent study of 152 patients treated with SBRT of 40 to 60 224 
Gy in five fractions, SUVmax was a significant predictor of OS, disease-free survival, and 225 
LP [14], although this study included patients with pathologically unconfirmed NSCLC.  226 
Another analysis showed that pre-treatment SUVmax was a significant predictor for 227 
disease-free survival and distant failure in 82 patients [12]. Burdick et al. evaluated the 228 
pre-treatment SUVmax in 72 patients treated with SBRT with a median follow-up of 16.9 229 
months, however SUVmax did not predict OS and DP [15]. We found a correlation 230 
between SUVmax and DP, although there was no statistically significant correlation with 231 
DP.  232 
The conventional PET scan has several problems for evaluation of SUVmax. First, the 233 
spatial resolution of the PET scanner is low. Second, the PET image is often blurred due 234 
to respiratory motion, especially in the lower lobes of the lung and upper abdominal 235 
organs. SUVmax is higher when measured using respiratory gating PET or CT 236 
reconstruction than when using conventional techniques in lung tumours [19]. If we had 237 
used the respiratory gating method in this study, a significant difference might have been 238 
observed. 239 
The use of DW-MRI for predicting the therapeutic effect and prognosis is also 240 
controversial. To date, no published study has addressed DWI in early-stage NSCLC 241 
patients treated with SBRT. A few reports have discussed DW-MRI and lung cancer 242 
treated with chemoradiotherapy. Ohno et al. reported a correlation between DW-MRI and 243 
PET in a study of 64 patients with locally advanced NSCLC (stage III) treated with 244 
conventional chemoradiotherapy. They found that higher ADC and SUVmax values were 245 
significantly associated with poor prognosis. OS and progression-free survival of the two 246 
groups split at an ADC value of 2.1 × 10-3 mm2/s, and a SUVmax of 10 showed a 247 
significant difference [20]. Several studies have suggested that the ADC value is a 248 
predictive factor for other organs. In a study that analysed 32 patients with 249 
hypopharyngeal or oropharyngeal squamous cell carcinoma who underwent pre-treatment 250 
DWI and definitive chemoradiotherapy, patients with a higher ADC value (more than 251 
median, 0.79 × 10-3 mm2/s) had a significantly lower local control rate than patients with a 252 
lower ADC value [21]. In contrast, Micco et al. reported that lower average pre-treatment 253 
ADC values were associated with high-risk features such as International Federation of 254 
Gynaecology and Obstetrics (FIGO) stage and LN metastases [10]. In another study, a 255 
lower ADC value was associated with shorter cancer-specific survival in patients with 256 
upper urinary tract cancer treated only with surgery [11]. Our result of a lower ADC value 257 
being associated with a poor prognosis after SBRT is in agreement with the latter reports. 258 
Several factors may have caused the different results. First, these studies defined ADC 259 
value differently. Different measures may be used to define the ROI and evaluate the 260 
ADC values, for example, using a minimum ADC value, a mean ADC value, or 261 
histogram analysis, etc [22-24]. We used the mean ADC value and avoided the cystic and 262 
necrotic areas to not affect the ADC value of the tumour. Second, the cancer type, clinical 263 
stage, and treatment strategies were different between the studies. 264 
Some negative correlations between ADC value and cell density have been 265 
observed in certain malignancies. Tumours with a lower ADC value are more likely to 266 
have viable proliferative cells, which are sensitive to chemotherapy and radiotherapy. 267 
Conversely, the presence of inflammatory changes, necrosis, and fibrosis influence ADC 268 
value, which is correlated with interstitial water content and low cell density in 269 
histological samples [25, 26]. The lower the ADC value, the more effective the 270 
chemotherapy and/or radiotherapy [10, 20, 27]. 271 
Tumour size, patient gender, and operability are other prognostic factors suggested 272 
for early stage NSCLC treated with SBRT [5, 28. 29]. Our results suggest that the 273 
functional imaging modalities such as DW-MRI and PET could be a good predictor of 274 
clinical outcomes. 275 
A limitation of this study is that the sample size was small. We introduced internal 276 
fiducial markers to a part of lung cancer patients in October 2010 to improve tumour 277 
localization during SBRT. The fiducial markers were made of gold and were inserted into 278 
bronchiole near the tumour [30]. Then, we stopped patient enrolment into the present 279 
study because of a concern that the gold markers might spoil image quality of DW-MRI. 280 
Despite of the small number, the present study indicated pre-treatment DW-MRI could be 281 
a predictor for clinical outcomes. A future study is warranted to prospectively evaluate the 282 
additional role of DW-MRI to FDG-PET before lung SBRT. 283 
The present study did not evaluate ADC values after SBRT. There are some 284 
studies investigating the use of DW-MRI for predicting therapeutic effect of 285 
chemoradiation by comparing ADC values before and after treatment. Liu et al reported 286 
the percentage ADC value change after 1 month correlated positively with size reduction 287 
after 2 months of chemoradiation in 17 patients with cervical cancer [27]. Another study 288 
reported the ADC value at the time of 20 Gy was significantly higher in responders 289 
compared to non-responders in 27 patients with primary clinical T4 oesophageal 290 
carcinoma treated with chemoradiation [31]. We are planning a study to evaluate 291 
usefulness of DW-MRI in evaluation of the tumour response after SBRT and in 292 
distinction of treatment-related change from recurrence. 293 
The consideration of more intensive therapy to prevent disease progression especially in 294 
high-risk patient is warranted. For example, dose escalation such as peripheral dose 295 
prescription and heterogeneous distribution, or systemic chemotherapy. However, early 296 
stage NSCLC patients treated with SBRT are often elderly and cannot tolerate 297 
chemotherapy. Thus, dose escalation is considered an appropriate strategy. 298 
 299 
Conclusion 300 
A low ADC value on pre-treatment DW-MRI and higher SUVmax may be associated with 301 
DP in NSCLC patients after SBRT. The combined use of ADC value and SUVmax is a 302 
better predictor for DP. 303 
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Table 1. Patients’ characteristics (n =15) 
Sex (male/female) 11/4 
Age (years), median (range) 80, (70–86)  
Performance status 0/1 11/4 
Operability  
 Operable/Inoperable 7/8 
Smoking status  
 Never smoker/ex-smoker 2/13 
Histology  
 Adenocarcinoma/SCC/NSCLC nos 7/6/2 
Size of tumour (mm), median (range) 30, (14–42) 
T stage  
 T1a/T1b/T2a 4/6/5 
Location  
 Peripheral/Central 9/6 
 RUL/RML/RLL/LUL/LLL 4/1/4/3/3 
Prescribed dose  
 48 Gy/56 Gy/60 Gy 5/4/6 
Abbreviations: SCC = squamous cell carcinoma; NSCLC nos = non-small cell lung cancer, not otherwise 
specified; RUL = right upper lung; RML = right middle lung; RLL = right lower lung; LUL = left upper 
lung; LLL = left lower lung. T stage was revised according to the 7th edition of the TNM classification for 
lung cancer. 
  
Table 2. Patients’ characteristics in the high- and low-risk groups. 
The high-risk group consisted of patients with an apparent diffusion coefficient (ADC) 
value ≤ 1.05 × 10-3 mm2/s and maximum standardised uptake values (SUVmax ) ≥ 7.9. 
The other patients were in the low-risk group. The two groups were not different 
statistically. 
 High-risk group (n 
= 8) 
Low-risk group 
(n = 7) 
Sex (male/female) 6/2 5/2 
Age (years), median 72–86, 80 70–83, 80 
Performance status 0/1 6/2 5/2 
Operability   
 Operable/Inoperable 4/4 3/4 
Smoking status   
 Never smoker/ex-smoker 0/8 2/5 
Histology   
 Adenocarcinoma/SCC/NSCLC nos 4/3/1 3/3/1 
Size of tumour (mm), median (range) 28.5(17–35) 30(14–42) 
T stage   
 T1a/T1b/T2a 2/3/3 2/3/2 
Prescribed dose   
 48 Gy/56 Gy/60 Gy 3/2/3 2/2/3 
Abbreviations: SCC = squamous cell carcinoma; NSCLC nos = non-small cell lung cancer, not otherwise 




Fig. 1. Scatter plot of the apparent diffusion coefficient (ADC) value and maximum 
standardised uptake (SUVmax). There was no statistical correlation between ADC value 
and SUVmax (r = 0.046). 
 
Fig. 2. Scatter plot of the apparent diffusion coefficient (ADC) value and tumour 
diameter (A) and maximum standardised uptake (SUVmax) and tumour diameter (B). 
There was no statistical correlation (p=0.64 and 0.63, respectively). 
 
Fig. 3. Cumulative incidence of disease progression (DP) according to apparent diffusion 
coefficient (ADC) value (A), maximum standardised uptake (SUVmax) (B), and the 
combination of ADC value and SUVmax (C). The group with the lower ADC value and 
higher SUVmax tended to have worse prognosis, although this result was not significantly 
significant (p = 0.09 and 0.32, respectively). When applying an optimal cut-off value of 
the ADC and SUVmax, the lower ADC value and higher SUVmax group had a significantly 




Fig. 1. Scatter plot of the apparent diffusion coefficient (ADC) value and maximum 
standardised uptake (SUVmax). There was no statistical correlation between ADC value 














































 Fig. 2. Scatter plot of the (A) apparent diffusion coefficient (ADC) value and tumour 
diameter and (B) maximum standardised uptake (SUVmax) and tumour diameter. There 




















Fig. 3. Cumulative incidence of disease progression (DP) according to apparent diffusion 
coefficient (ADC) value (A), maximum standardised uptake (SUVmax) (B), and the 
combination of ADC value and SUVmax (C). The group with the lower ADC value and 
higher SUVmax tended to have worse prognosis, although this result was not significantly 
significant (p = 0.09 and 0.32, respectively). When applying an optimal cut-off value of 
the ADC and SUVmax, the lower ADC value and higher SUVmax group had a significantly 
poorer prognosis (p = 0.036); the combination was a strong predictor for DP. 
 
